AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 12053829
Drug: Prevention and
RxNorm normalized name: PINE NEEDLE OIL (PINUS MUGO) 5 mg in 100 mL TOPICAL LIQUID [JEUNCELL Hair Loss Prevention and Hair Growth Tonic]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prevention and treatment strategies for traveller's diarrhoea
Trial: 9455509
Drug: Topical paromomycin/MBCL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical paromomycin/MBCL plus injectable Sb for 7 days
Trial: 7658950
Drug: Drink with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drink with 6% carbohydrates and 0 mmol.l‐1 Na+
Trial: 7658950
Drug: Drink with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drink with 6% carbohydrates and 8.8 mmol.l‐1 Na+
Trial: 7658950
Drug: Drink with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drink with 6% carbohydrates and 18.5 mmol.l‐1 Na+
Trial: 3967455
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg amantadine
Trial: 16794570
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg amantadine
Trial: 16794570
Drug: Amantadine (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amantadine (50 mg and 100 mg)
Trial: 8809929
Drug: Exercise program
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exercise program (twice a week for 8 weeks)
Trial: 7941802
Drug: Intravenous glucose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous glucose 5% plus electrolytes, neostigmine, and dexpanthenon (Group A)
Trial: 7941802
Drug: Standardized commercially
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standardized commercially available solutions without intravenous stimulation of the bowel (Group B)
Trial: 30961913
Drug: Recruitment manoeuvres
RxNorm normalized name: Humanized Bi-Specific Xmab(R) T Cell Recruiting Antibody Construct Directed Against Cd3 And Cd38
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recruitment manoeuvres with PEEP titration
Trial: 15005472
Drug: Atraumatic restorative
RxNorm normalized name: DRESSING,RESTORE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atraumatic restorative treatment (ART) using Fuji IX GP and Ketac‐Molar Aplicap in Class II cavities
Trial: 15005472
Drug: Conventional cavity
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional cavity preparation using Fuji IX GP and Ketac‐Molar Aplicap in Class II cavities
Trial: 15005472
Drug: Atraumatic restorative
RxNorm normalized name: DRESSING,RESTORE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atraumatic restorative treatment (ART) using Fuji IX GP and Ketac‐Molar Aplicap in Class I cavities
Trial: 3062082
Drug: Ursodeoxycholic acid
RxNorm normalized name: Ursodeoxycholic acid
DrugBank: Ursodeoxycholic acid (DB01586)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ursodeoxycholic acid 250 mg/day
Trial: 3062082
Drug: Ursodeoxycholic acid
RxNorm normalized name: Ursodeoxycholic acid
DrugBank: Ursodeoxycholic acid (DB01586)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ursodeoxycholic acid 500 mg/day
Trial: 3062082
Drug: Ursodeoxycholic acid
RxNorm normalized name: Ursodeoxycholic acid
DrugBank: Ursodeoxycholic acid (DB01586)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ursodeoxycholic acid 750 mg/day
Trial: 26399865
Drug: Vitamin D3
RxNorm normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D3 (50,000 IUs thrice weekly for 8 weeks and 50,000 IU every other week for 8 weeks)
Trial: 19586799
Drug: Simvastatin/Ezetimibe 40/10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simvastatin/Ezetimibe 40/10 mg daily
Trial: 15152874
Drug: Cefditoren twice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefditoren twice a day for 10 days
Trial: 15152874
Drug: Cefuroxim twice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefuroxim twice a day for 10 days
Trial: 9848851
Drug: N-methyl-D-aspartate receptor
RxNorm normalized name: N-methyl-D-aspartate receptor antibody
FDA approved: no
EMA approved: no
PMDA approved: no
Description: N-methyl-D-aspartate receptor antagonist Selfotel
Trial: 19756416
Drug: Glucosamine sulfate
RxNorm normalized name: Glucosamine Sulfate
DrugBank: Glucosamine (DB01296)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Glucosamine sulfate (1500 mg/day) + omega-3 fatty acids (EPA and DHA)
Trial: 15253739
Drug: Vitamin C
RxNorm normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin C (300 mg, intravenous sodium ascorbate)
Trial: 2881320
Drug: 0.02 mcg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.02 mcg/kg CCK‐8
Trial: 2881320
Drug: 0.04 mcg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.04 mcg/kg CCK‐8
Trial: 22652582
Drug: PCV7 (1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PCV7 (1.0 mL)
Trial: 16002808
Drug: Phosphatidylcholine supplementation
RxNorm normalized name: phosphatidylcholine, soybean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phosphatidylcholine supplementation (2.6 g choline/d)
Trial: 16002808
Drug: Phosphatidylcholine (1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phosphatidylcholine (1.5 g choline) on the first day of supplementation
Trial: 8554943
Drug: Pancopride 10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pancopride 10 mg
Trial: 8554943
Drug: Pancopride 5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pancopride 5 mg
Trial: 1782064
Drug: Continuous intravenous
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous intravenous infusion of 20 mg/m2 per day on days 1‐5 and 22‐26 with irradiation on days 2, 5, 9, 16, 23 and 26
Trial: 1782064
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg cisplatin over 24 h commencing 1 h before each fraction of irradiation on days 1, 4, 8, 11, 15 and 18
Trial: 21909502
Drug: Preoperative oral
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Preoperative oral squamous cell carcinoma patients
Trial: 21909502
Drug: Postoperative oral
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Postoperative oral squamous cell carcinoma patients
Trial: 21909502
Drug: Oral squamous
RxNorm normalized name: Vespula squamosa venom protein
DrugBank: Vespula squamosa venom protein (DB11032)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral squamous cell carcinoma patients (both groups)
Trial: 2666532
Drug: Oral steroid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral steroid CME treatment
Trial: 16548360
Drug: Biqi capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biqi capsule (BC)
Trial: 10769442
Drug: Dacron patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dacron patch
Trial: 8842602
Drug: Buccal GLP-I
RxNorm normalized name: iobenguane I-131
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buccal GLP-I tablet (119 nmol)
Trial: 6360325
Drug: 5-fluorouracil and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5-fluorouracil and methyl-CCNU administered in combination, given in discrete 5-day courses at 7-week intervals.
Trial: 27548104
Drug: Lenvatinib (24
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lenvatinib (24 mg once daily)
Trial: 15791501
Drug: Clodronate 400
RxNorm normalized name: clodronic acid 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clodronate 400 mg; 1200 mg/day (p.o.)
Trial: 2937673
Drug: Sicorten cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sicorten cream
Trial: 2937673
Drug: Sicorten ointment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sicorten ointment
Trial: 18715405
Drug: 3 mg
RxNorm normalized name: boron 3 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 mg of cetrorelix (4-7 days)
Trial: 12859157
Drug: Alternating therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alternating therapy (regimen C)
Trial: 10368202
Drug: Topical vasoactive
RxNorm normalized name: Vasoactive intestinal peptide
DrugBank: Vasoactive intestinal peptide (DB18634)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical vasoactive cream (aminophylline, isosorbide dinitrate, co-dergocrine mesylate)
Trial: 10368202
Drug: Placebo cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo cream (no pharmacologically active ingredients)
Trial: 1997243
Drug: Repair and
RxNorm normalized name: Pantene Repair And Protect Shampoo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Repair and augmentation of the ACL with an iliotibial strip
Trial: 31451579
Drug: Clobazam (GABAA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clobazam (GABAA modulator)
Trial: 31451579
Drug: Arbaclofen (GABAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Arbaclofen (GABAB modulator)
Trial: 28974349
Drug: Reduced-dose ICS/LABA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reduced-dose ICS/LABA
Trial: 26489028
Drug: Low-dose intravenous
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose intravenous cyclophosphamide (CYC)
Trial: 26489028
Drug: Oral mycophenolate
RxNorm normalized name: mycophenolate
DrugBank: Mycophenolic acid (DB01024)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral mycophenolate mofetil (MMF)
Trial: 17115180
Drug: Glutamine (0.125
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glutamine (0.125 g kg body mass(‐1))
Trial: 31096728
Drug: General anesthesia
RxNorm normalized name: Ethers for general anesthesia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: General anesthesia (Group G)
Trial: 28272120
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy (Imipramine + Pregabalin)
Trial: 28272120
Drug: Imipramine (monotherapy)
DrugBank: Imipramine (DB00458)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Imipramine (monotherapy)
Trial: 28272120
Drug: Pregabalin (monotherapy)
RxNorm normalized name: Pregabalin
DrugBank: Pregabalin (DB00230)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Pregabalin (monotherapy)
Trial: 15786695
Drug: Cabergoline at
RxNorm normalized name: Cabergoline
DrugBank: Cabergoline (DB00248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cabergoline at 0.5 mg/week orally for 4 consecutive weeks
Trial: 8005305
Drug: No therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No therapy (Control group)
Trial: 17244442
Drug: Intraocular injections
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraocular injections of steroids and anti-vascular endothelial growth factor agents
Trial: 17244442
Drug: Sustained drug
RxNorm normalized name: Sustain
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sustained drug release devices
Trial: 22032832
Drug: Transdermal nicotine
RxNorm normalized name: nicotine Transdermal System
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Transdermal nicotine (21 mg)
Trial: 6216427
Drug: Locoid scalp
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Locoid scalp lotion
Trial: 31502856
Drug: Laser Acupuncture
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Laser Acupuncture (LA), administered at traditional Chinese acu-points on the affected side, once a day, 5 times a week, for 4 weeks (N=43)
Trial: 31502856
Drug: Placebo Laser
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo Laser Acupuncture (placebo LA), administered using the same device and protocol, with the LA device switched off (N=41)
Trial: 19643944
Drug: Weekly, supervised,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weekly, supervised, outpatient‐based exercise plus unsupervised home exercise
Trial: 12182992
Drug: Diphenoxylate and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diphenoxylate and atropine orally, 2.5 mg four times daily (n = 28)
Trial: 12182992
Drug: Octreotide s.c.,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Octreotide s.c., 100 microg three times daily (n = 33)
Trial: 20976161
Drug: Fish oil
RxNorm normalized name: Fish oil
DrugBank: Fish oil (DB13961)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fish oil (3.2 g EPA and 2.0 g DHA)
Trial: 20976161
Drug: Combination treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination treatment (Montelukast + Fish oil)
Trial: 20976161
Drug: Fish oil
RxNorm normalized name: Fish oil
DrugBank: Fish oil (DB13961)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fish oil and Combination treatment
Trial: 11963645
Drug: Test formulation
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Test formulation (Dilavenil)
Trial: 9811158
Drug: Mibefradil 50
RxNorm normalized name: mibefradil 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mibefradil 50 mg once daily for 8 days
Trial: 9811158
Drug: Mibefradil 100
RxNorm normalized name: mibefradil 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mibefradil 100 mg once daily for 8 days
Trial: 9811158
Drug: Mibefradil 150
RxNorm normalized name: mibefradil
DrugBank: Mibefradil (DB01388)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mibefradil 150 mg once daily for 8 days
Trial: 9811158
Drug: Mibefradil 200
RxNorm normalized name: mibefradil
DrugBank: Mibefradil (DB01388)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mibefradil 200 mg once daily for 8 days
Trial: 9811158
Drug: Mibefradil 40
RxNorm normalized name: mibefradil
DrugBank: Mibefradil (DB01388)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mibefradil 40 mg intravenous dose
Trial: 2522756
Drug: Organoclay preparation
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Organoclay preparation
Trial: 12441211
Drug: lacidipine 2
RxNorm normalized name: lacidipine 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: lacidipine 2 mg/day
Trial: 1906692
Drug: 150 mg
RxNorm normalized name: pectin 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 mg rt-PA
Trial: 1906692
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg rt-PA
Trial: 7723950
Drug: rt-PA (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rt-PA (150 mg or 100 mg)
Trial: 6779303
Drug: Chlormethiazole (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chlormethiazole (1 g at bedtime and 0.5 g early the following morning)
Trial: 23684138
Drug: Oral ciprofloxacin
RxNorm normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral ciprofloxacin (500 mg) 1 hour before procedure (Group 2, n = 141)
Trial: 23684138
Drug: Single dose
RxNorm normalized name: Citrucel Single Dose Packets (Orange)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of fosfomycin tromethamine (FT) approximately 12 hours before procedure (Group 3, n = 137)
Trial: 12140392
Drug: Losartan potassium
RxNorm normalized name: Losartan Potassium
DrugBank: Losartan (DB00678)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Losartan potassium (50 mg)
Trial: 30659024
Drug: Osimertinib (80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Osimertinib (80 mg orally, once daily)
Trial: 29743071
Drug: First-line coil
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: First-line coil treatment
Trial: 19213339
Drug: CT‐F (chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CT‐F (chemotherapy with FOLFOX protocol)
Trial: 15908833
Drug: Clinic-administered, abstinence-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clinic-administered, abstinence-based incentive program; parent-directed contingency management; clinic-administered incentive program for parent participation; individual cognitive-behavioral therapy
Trial: 6337742
Drug: Isosorbide dinitrate
RxNorm normalized name: Isosorbide Dinitrate
DrugBank: Isosorbide dinitrate (DB00883)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Isosorbide dinitrate (40 mg orally)
Trial: 22984818
Drug: Bladder filling
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bladder filling with normal saline prior to trial of void (up to 500 mL or first sensation of fullness)
Trial: 17686555
Drug: HCV peptide-vaccine
RxNorm normalized name: peptide-T
DrugBank: Peptide-T (DB19279)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HCV peptide-vaccine IC41
Trial: 7942475
Drug: Intracoronary phentolamine,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intracoronary phentolamine, 2 mg, infused regionally through the balloon catheter before coronary artery angioplasty (n=12)
Trial: 2894161
Drug: rilmenidine (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rilmenidine (0.5 mg)
Trial: 2894161
Drug: rilmenidine (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rilmenidine (1 mg)
Trial: 2894161
Drug: rilmenidine (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rilmenidine (2 mg)
Trial: 26286147
Drug: Qing-Feng-Gan-Ke Granules
RxNorm normalized name: qing feng teng stem extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Qing-Feng-Gan-Ke Granules (QFGKG) 12.0 g twice daily
Trial: 26286147
Drug: Placebo 12.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo 12.0 g twice daily
Trial: 22729212
Drug: High-dose NRT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose NRT (31.2 mg for the first 4 weeks, then 20.8 mg for 4 weeks)
Trial: 22729212
Drug: Low-dose NRT
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose NRT (20.8 mg for 8 weeks)
Trial: 25946654
Drug: Low-dose rosuvastatin
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose rosuvastatin (5 mg)
Trial: 18294500
Drug: High-dose rosuvastatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose rosuvastatin (40/80 mg)
Trial: 18975103
Drug: Galantamine (16
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Galantamine (16 mg/day)
Trial: 2644747
Drug: Midazolam 0.075
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midazolam 0.075 mg/kg i.v.
Trial: 811427
Drug: Isosorbide dinitrate
RxNorm normalized name: Isosorbide Dinitrate
DrugBank: Isosorbide dinitrate (DB00883)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Isosorbide dinitrate (sublingual or oral)
Trial: 28732453
Drug: Tyrosine kinase
RxNorm normalized name: Protein-tyrosine kinase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tyrosine kinase inhibitors (sunitinib, pazopanib, axitinib, sorafenib)
Trial: 28732453
Drug: Adverse events
RxNorm normalized name: iodine
DrugBank: Iodine (DB05382)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Adverse events of special interest treatment (pharmacologic and/or nonpharmacologic)
Trial: 28732453
Drug: Tyrosine kinase
RxNorm normalized name: Protein-tyrosine kinase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tyrosine kinase inhibitor dose management
Trial: 28732453
Drug: Neither treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neither treatment nor dose management
Trial: 28732453
Drug: Treatment for
RxNorm normalized name: Hair Regrowth Treatment For Men
DrugBank: Minoxidil (DB00350)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Treatment for fatigue
Trial: 16521844
Drug: GEL
RxNorm normalized name: Gel
DrugBank: Sepia esculenta bone (DB16562)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GEL
Trial: 30753355
Drug: Control (Nongametocytocidal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (Nongametocytocidal drugs)
Trial: 25155992
Drug: Carboxymethylcellulose (CMC)
DrugBank: Carboxymethylcellulose (DB11059)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carboxymethylcellulose (CMC) (16 g total fiber/day)
Trial: 25155992
Drug: Gum arabic
RxNorm normalized name: Gum arabic
DrugBank: Acacia (DB10451)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gum arabic (GA) (16 g total fiber/day)
Trial: 20610931
Drug: Posaconazole 200
RxNorm normalized name: posaconazole 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Posaconazole 200 mg per os TID
Trial: 9833600
Drug: Lisinopril 20
RxNorm normalized name: lisinopril 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lisinopril 20 mg once daily for 6 weeks
Trial: 9833600
Drug: Losartan 50
RxNorm normalized name: LOSARTAN 50MG TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Losartan 50 mg once daily for 6 weeks
Trial: 8026247
Drug: Cimetropium bromide
RxNorm normalized name: cimetropium bromide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cimetropium bromide 10 mg intravenously over 3 min
Trial: 2596070
Drug: Antioxidant complex
RxNorm normalized name: antioxidant 119
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antioxidant complex (vitamins C, E, and A) administered preoperatively
Trial: 335687
Drug: Pindolol (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pindolol (2 X 2 tablets per 5 mg daily) and Trichlormethiazidum (1 X 1 tablet per 4 mg daily)
Trial: 28856858
Drug: HIFU treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HIFU treatment with SonoVue at 1 minute after administration
Trial: 28856858
Drug: HIFU treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HIFU treatment only (control group)
Trial: 26324372
Drug: Erlotinib 150
RxNorm normalized name: erlotinib 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erlotinib 150 mg once per day for 2 years
Trial: 23490328
Drug: ESBA105 6.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ESBA105 6.4 mg (cohort III)
Trial: 23490328
Drug: ESBA105 3.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ESBA105 3.2 mg (cohorts II and IV)